http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : M. A. Elbaset (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
M.A. Elbaset,Diaa-Eldin Taha,Ahmed S. El-Hefnawy,Mohamad H. Zahran,A.A Shokeir 대한배뇨장애요실금학회 2019 International Neurourology Journal Vol.23 No.3
Purpose: To evaluate the efficacy and safety of re-treatment with anticholinergics on refractory idiopathic overactive bladder (OAB) previously treated with intravesical botulinum neurotoxin type A (BTX-A) injections. Methods: One hundred patients were initially managed by intravesical injections of 100 IU of BTX-A. After the effects of BTX-A faded, patients were randomized into 2 groups: group A patients received solifenacin (10 mg) for 12 weeks (study group), while group B patients received placebo treatment for 12 weeks (control group), then subsequently received solifenacin (10 mg) for another 6 weeks. All patients underwent preoperative urodynamic testing. Patients were asked to complete the validated overactive bladder symptoms score (OABSS) and incontinence quality of life (I-QoL) instruments after the effects of intravesical BTX-A faded and at 12 weeks of follow-up. Univariate and multivariate analyses of the factors affecting treatment response were conducted. Results: At 12 weeks of follow-up, in group A, all OABSS items, including the total score, had improved significantly (P<0.0001). Group A had lower frequency and amplitude of detrusor overactivity and detrusor leak point pressure (P<0.0001, P=0.03, and P=0.01, respectively). Cystometric capacity also increased significantly (P=0.007), as did all I-QoL parameters. In a comparison of patients with failed treatment and patients with successful treatment, female sex, repeated intravesical BTX-A injections, and increased bladder capacity were statistically significant (P=0.001, P=0.0001, and P=0.002, respectively). Repeated intravesical BTX-A injections and increased bladder capacity were independent factors predicting treatment success. Conclusions: In patients with refractory idiopathic OAB, reuse of anticholinergics could be an effective treatment option in patients after the effects of BTX-A fade. Repeated intravesical BTX-A injections and increased cystometric capacity could affect treatment response.
-
Abdelwahab Hashem,Fady K. Ghobrial,M. A. Elbaset,Ahmed M. Atwa,Mohamed Fadallah,Mahmoud Laymon,Ahmed El-Assmy,Khaled Z. Sheir,Hassan Abol-Enein 대한비뇨의학회 2019 Investigative and Clinical Urology Vol.60 No.4
Purpose: To compare the safety and efficacy of xylocaine gel and ketorolac as opioid-sparing analgesia compared with pethidine for shock wave lithotripsy (SWL) pain. Materials and Methods: A single-blinded randomized controlled trial (RCT) was performed in 132 patients with renal and upper ureteral stones amenable to treatment with SWL. The first patient group received intravenous (IV) pethidine and placebo gel; the second group received IV ketorolac plus placebo gel; the third group received lidocaine gel locally plus normal saline IV. Stone disintegration was classified as none (no change from basal by kidney, ureter, bladder X-ray or ultrasound [US] imaging), partial (fragmented and >4-mm residual fragments), and complete (≤4-mm residual fragments). Stone disintegration was assessed by kidney-ureter-bladder X-ray and US imaging. Pain was evaluated by use of the Numeric Pain Rating Scale (NPRS). Results: The NPRS scores were highest in the xylocaine group at 10, 20, and 30 minutes (p=0.0001) with no significant difference between the ketorolac and pethidine groups, except at 10 minutes (p=0.03) and a near significant difference at 30 minutes (p=0.054) in favor of ketorolac. Results for stone disintegration (none, partial, and complete, respectively) were as follows: 25 (50.0%), 23 (46.0%), and 2 (4.0%) for pethidine; 19 (35.8%), 23 (43.4%), and 11 (20.8%) for ketorolac; and 26 (89.7%), 3 (10.3%), and 0 (0.0%) for lidocaine (p=0.008). Conclusions: Ketorolac is a safe and more effective alternative to morphine derivatives for SWL analgesia. Lidocaine gel should not be used as mono-analgesia for SWL.
-
Noha F. Abdelkader,Marawan A. Elbaset,Passant E. Moustafa,Sherehan M. Ibrahim 대한약학회 2022 Archives of Pharmacal Research Vol.45 No.7
Diabetic peripheral neuropathy (DPN) representsa severe microvascular condition that dramatically affectsdiabetic patients despite adequate glycemic control, resultingin high morbidity. Thus, recently, anti-diabetic drugsthat possess glucose-independent mechanisms attractedattention. This work aims to explore the potentiality of theselective sodium-glucose cotransporter-2 inhibitor, empagliflozin (EMPA), to ameliorate streptozotocin-induced DPNin rats with insight into its precise signaling mechanism. Rats were allocated into four groups, where control animalsreceived vehicle daily for 2 weeks. In the remaining groups,DPN was elicited by single intraperitoneal injections offreshly prepared streptozotocin and nicotinamide (52.5 and50 mg/kg, respectively). Then EMPA (3 mg/kg/p.o.) wasgiven to two groups either alone or accompanied with theAMPK inhibitor dorsomorphin (0.2 mg/kg/i.p.). Despite thenon-significant anti-hyperglycemic effect, EMPA improvedsciatic nerve histopathological alterations, scoring, myelination,nerve fibers’ count, and nerve conduction velocity. Moreover, EMPA alleviated responses to different nociceptivestimuli along with improved motor coordination. EMPAmodulated ATP/AMP ratio, upregulated p-AMPK whilereducing p-p38 MAPK expression, p-ERK1/2 and consequentlyp-NF-κB p65 as well as its downstream mediators (TNF-α and IL-1β), besides enhancing SOD activity andlowering MDA content. Moreover, EMPA downregulatedmTOR and stimulated ULK1 as well as beclin-1. Likewise,EMPA reduced miR-21 that enhanced RECK, reducingMMP-2 and -9 contents. EMPA’s beneficial effects werealmost abolished by dorsomorphin administration. In conclusion,EMPA displayed a protective effect against DPNindependently from its anti-hyperglycemic effect, probablyvia modulating the AMPK pathway to modulate oxidativeand inflammatory burden, extracellular matrix remodeling,and autophagy.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
